These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29548051)

  • 41. Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials.
    Sharma N; Mallela AN; Shi DD; Tang LW; Abou-Al-Shaar H; Gersey ZC; Zhang X; McBrayer SK; Abdullah KG
    Neurooncol Adv; 2023; 5(1):vdad053. PubMed ID: 37287696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues.
    Rudà R
    Neuro Oncol; 2023 Jan; 25(1):26-27. PubMed ID: 36245275
    [No Abstract]   [Full Text] [Related]  

  • 43. Current concepts in the evaluation and management of WHO grade II gliomas.
    Piepmeier JM
    J Neurooncol; 2009 May; 92(3):253-9. PubMed ID: 19357953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contemporary management of high-grade gliomas.
    Sim HW; Morgan ER; Mason WP
    CNS Oncol; 2018 Jan; 7(1):51-65. PubMed ID: 29241354
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An analysis of prognostic factors in a cohort of low-grade gliomas and degree of consistency between RTOG and EORTC scores.
    Pérez IF; Valverde D; Valverde CF; Iglesias JB; Silva MJV; Quintela ML; Meléndez B
    Sci Rep; 2022 Sep; 12(1):16433. PubMed ID: 36180501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paediatric type diffuse high grade gliomas in the WHO CNS5 classification: What the pathologist needs to know?
    Rao S; Sahay A; Epari S
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S50-S58. PubMed ID: 35562134
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Caring for Patients with Newly Diagnosed High-Grade Gliomas.
    Grossman SA; Piotrowski AF
    Semin Neurol; 2016 Aug; 36(4):324-9. PubMed ID: 27643899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dogs are man's best friend: in sickness and in health.
    Bentley RT; Ahmed AU; Yanke AB; Cohen-Gadol AA; Dey M
    Neuro Oncol; 2017 Mar; 19(3):312-322. PubMed ID: 27298310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renin angiotensin system and its role in biomarkers and treatment in gliomas.
    Perdomo-Pantoja A; Mejía-Pérez SI; Gómez-Flores-Ramos L; Lara-Velazquez M; Orillac C; Gómez-Amador JL; Wegman-Ostrosky T
    J Neurooncol; 2018 May; 138(1):1-15. PubMed ID: 29450812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and promising treatment strategies in glioma.
    Śledzińska P; Bebyn M; Furtak J; Koper A; Koper K
    Rev Neurosci; 2023 Jul; 34(5):483-516. PubMed ID: 36062548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiology and Overview of Gliomas.
    Davis ME
    Semin Oncol Nurs; 2018 Dec; 34(5):420-429. PubMed ID: 30392758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma.
    Bombino A; Magnani M; Conti A
    Curr Mol Pharmacol; 2024 Feb; ():. PubMed ID: 38425121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epigenetic Reprogramming for Targeting
    Park JW; Turcan Ş
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31652645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of low-grade pediatric gliomas.
    Schmandt SM; Packer RJ
    Curr Opin Oncol; 2000 May; 12(3):194-8. PubMed ID: 10841190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional nanoparticles in targeting glioma diagnosis and therapies.
    Li M; Deng H; Peng H; Wang Q
    J Nanosci Nanotechnol; 2014 Jan; 14(1):415-32. PubMed ID: 24730272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update.
    Frosina G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results.
    Singer LS; Feldman AZ; Buerki RA; Horbinski CM; Lukas RV; Stupp R
    Chin Clin Oncol; 2021 Aug; 10(4):38. PubMed ID: 34118826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response assessment challenges in clinical trials of gliomas.
    Wen PY; Norden AD; Drappatz J; Quant E
    Curr Oncol Rep; 2010 Jan; 12(1):68-75. PubMed ID: 20425610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence-based Treatment for Low-grade Glioma.
    Semmel D; Ware C; Kim JY; Peters KB
    Semin Oncol Nurs; 2018 Dec; 34(5):465-471. PubMed ID: 30391119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in the diagnosis and management of cerebral gliomas.
    Brady LW
    Am J Clin Oncol; 1987 Aug; 10(4):277. PubMed ID: 3618540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.